MA55951A - Nouveau gardnerella endolysins et utilisations correspondantes - Google Patents
Nouveau gardnerella endolysins et utilisations correspondantesInfo
- Publication number
- MA55951A MA55951A MA055951A MA55951A MA55951A MA 55951 A MA55951 A MA 55951A MA 055951 A MA055951 A MA 055951A MA 55951 A MA55951 A MA 55951A MA 55951 A MA55951 A MA 55951A
- Authority
- MA
- Morocco
- Prior art keywords
- endolysins
- gardnerella
- new
- related uses
- new gardnerella
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19173389 | 2019-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55951A true MA55951A (fr) | 2022-03-23 |
Family
ID=66476422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055951A MA55951A (fr) | 2019-05-08 | 2020-05-07 | Nouveau gardnerella endolysins et utilisations correspondantes |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220315908A1 (fr) |
| EP (1) | EP3969578A1 (fr) |
| JP (2) | JP2022532130A (fr) |
| KR (1) | KR20220007123A (fr) |
| CN (2) | CN120136980A (fr) |
| AU (2) | AU2020268752B2 (fr) |
| BR (1) | BR112021022283A2 (fr) |
| CA (1) | CA3136346A1 (fr) |
| CL (1) | CL2021002901A1 (fr) |
| IL (1) | IL287842A (fr) |
| MA (1) | MA55951A (fr) |
| MX (1) | MX2021013491A (fr) |
| SG (1) | SG11202111067YA (fr) |
| WO (1) | WO2020225335A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4247943A1 (fr) * | 2020-11-18 | 2023-09-27 | CC Biotech Ltd. | Polypeptides pour le traitement d'infections bactériennes |
| WO2023083434A1 (fr) * | 2021-11-09 | 2023-05-19 | BioNTech SE | Arn codant pour la peptidoglycane hydrolase et son utilisation pour le traitement d'une infection bactérienne |
| CN118804761A (zh) | 2022-02-11 | 2024-10-18 | 生物技术公司 | 加德纳菌内溶素的新型治疗用途 |
| DE102022213056A1 (de) | 2022-12-05 | 2024-06-06 | Universität Rostock, Körperschaft des öffentlichen Rechts | Innovative antimikrobielle Therapie gegen Streptococcus pneumoniae mittels mRNA kodierter Bakteriophagen-Endolysine/Autolysine |
| CN121079100A (zh) | 2023-05-09 | 2025-12-05 | 百欧恩泰欧洲股份公司 | 加德纳菌属内溶素的阴道内制剂 |
| WO2025002339A1 (fr) * | 2023-06-30 | 2025-01-02 | 上海赛增医疗科技有限公司 | Nouvelle lyase modifiée et son utilisation |
| WO2025024827A1 (fr) * | 2023-07-27 | 2025-01-30 | Topaz Biosciences, Inc. | Hydrolases de paroi cellulaire ciblant c. acnes |
| KR20260049580A (ko) | 2023-07-27 | 2026-04-14 | 토파즈 바이오사이언시스, 인크. | 씨. 아크네스를 표적화하는 세포벽 가수분해효소 |
| TW202541833A (zh) | 2023-12-12 | 2025-11-01 | 德商拜恩技術股份公司 | 包含內溶素之組合物及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0202556D0 (en) * | 2002-02-04 | 2002-03-20 | Danisco | Novel Protein |
| DK2037946T3 (en) * | 2006-05-05 | 2015-04-27 | Gangagen Inc | ANTIMICROBIAL ACTIVITIES DERIVED BY PHAGER |
| AU2008328584A1 (en) * | 2007-11-26 | 2009-06-04 | Plant Bioscience Limited | Novel polypeptides having endolysin activity and uses thereof |
| US20120171188A1 (en) * | 2008-08-19 | 2012-07-05 | Hyglos Invest Gmbh | Artificial Peptidoglycan Lysing Enzymes and Peptidoglycan Binding Proteins |
| EP2157100A1 (fr) * | 2008-08-19 | 2010-02-24 | Profos AG | Enzymes de lyse peptidoglycane artificielles et protéines à liaison de peptidoglycane |
| GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| SG178440A1 (en) * | 2009-08-24 | 2012-04-27 | Univ Leuven Kath | New endolysin obpgplys |
| EP2338916A1 (fr) * | 2009-12-23 | 2011-06-29 | Hyglos Invest GmbH | Polypeptides chimériques et leur utilisation dans la décolonisation bactérienne |
| EA037276B1 (ru) * | 2010-04-27 | 2021-03-03 | Лисандо Аг | Способы устранения или уменьшения бактериальной биопленки |
| GB201018518D0 (en) * | 2010-11-03 | 2010-12-15 | Univ Leuven Kath | Novel endolysin |
| EP2468856A1 (fr) * | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Agents antimicrobiens |
| US8790639B2 (en) * | 2012-03-28 | 2014-07-29 | The United States Of America, As Represented By The Secretary Of Agriculture | Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin |
| SG11201707345VA (en) * | 2015-03-12 | 2017-10-30 | Micreos Human Health Bv | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection |
| CN105062992B (zh) * | 2015-07-20 | 2018-05-11 | 昆明理工大学 | 一种细胞内溶素和编码此细胞内溶素的多核苷酸 |
| AU2018248060B2 (en) * | 2017-04-03 | 2024-05-23 | Sasinapas Co., Ltd. | Engineered Gram-negative endolysins |
| CN111471671B (zh) * | 2020-04-16 | 2022-04-12 | 中国农业大学 | 一种具有抑制产气荚膜梭菌活性的蛋白质及其相关生物材料与应用 |
| CN118804761A (zh) * | 2022-02-11 | 2024-10-18 | 生物技术公司 | 加德纳菌内溶素的新型治疗用途 |
-
2020
- 2020-05-07 CN CN202510234095.1A patent/CN120136980A/zh active Pending
- 2020-05-07 US US17/609,358 patent/US20220315908A1/en active Pending
- 2020-05-07 BR BR112021022283A patent/BR112021022283A2/pt unknown
- 2020-05-07 JP JP2021566252A patent/JP2022532130A/ja active Pending
- 2020-05-07 EP EP20722613.5A patent/EP3969578A1/fr active Pending
- 2020-05-07 KR KR1020217040214A patent/KR20220007123A/ko active Pending
- 2020-05-07 WO PCT/EP2020/062645 patent/WO2020225335A1/fr not_active Ceased
- 2020-05-07 MX MX2021013491A patent/MX2021013491A/es unknown
- 2020-05-07 CA CA3136346A patent/CA3136346A1/fr active Pending
- 2020-05-07 SG SG11202111067YA patent/SG11202111067YA/en unknown
- 2020-05-07 CN CN202080033977.7A patent/CN113795577B/zh active Active
- 2020-05-07 AU AU2020268752A patent/AU2020268752B2/en active Active
- 2020-05-07 MA MA055951A patent/MA55951A/fr unknown
-
2021
- 2021-11-04 CL CL2021002901A patent/CL2021002901A1/es unknown
- 2021-11-04 IL IL287842A patent/IL287842A/en unknown
-
2024
- 2024-11-28 JP JP2024207527A patent/JP2025026484A/ja active Pending
-
2026
- 2026-02-26 AU AU2026201469A patent/AU2026201469A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120136980A (zh) | 2025-06-13 |
| SG11202111067YA (en) | 2021-11-29 |
| US20220315908A1 (en) | 2022-10-06 |
| AU2020268752B2 (en) | 2025-12-18 |
| CN113795577A (zh) | 2021-12-14 |
| AU2020268752A1 (en) | 2021-12-02 |
| EP3969578A1 (fr) | 2022-03-23 |
| IL287842A (en) | 2022-01-01 |
| JP2022532130A (ja) | 2022-07-13 |
| BR112021022283A2 (pt) | 2021-12-28 |
| CL2021002901A1 (es) | 2022-06-03 |
| WO2020225335A1 (fr) | 2020-11-12 |
| CN113795577B (zh) | 2025-03-18 |
| MX2021013491A (es) | 2022-02-21 |
| KR20220007123A (ko) | 2022-01-18 |
| AU2026201469A1 (en) | 2026-03-19 |
| CA3136346A1 (fr) | 2020-11-12 |
| JP2025026484A (ja) | 2025-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55951A (fr) | Nouveau gardnerella endolysins et utilisations correspondantes | |
| MA50502A (fr) | Adénovirus et utilisations associées | |
| EP3762030A4 (fr) | Anticorps anti-cd73 et utilisations associées | |
| EP3749312A4 (fr) | Lométrexol alpha-polyglutamaté et utilisations associées | |
| EP3807321A4 (fr) | Constructions anti-mésothéline et utilisations associées | |
| IL283550A (en) | Chemically-modified rnai constructs and uses thereof | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| EP3749315A4 (fr) | Raltitrexed alpha-polyglutamaté et utilisations associées | |
| EP3749318A4 (fr) | Raltitrexed gamma-polyglutamaté et utilisations associées | |
| EP3838289A4 (fr) | Anticorps anti-tigit et ses utilisations | |
| EP3810182A4 (fr) | Néoantigènes et leurs utilisations | |
| EP3752156A4 (fr) | Pralatrexate gamma-polyglutamaté et utilisations associées | |
| EP3749316A4 (fr) | Pralatrexate alpha-polyglutamaté et utilisations associées | |
| EP3749314A4 (fr) | Méthotrexate alpha-polyglutamaté et utilisations associées | |
| EP3735427A4 (fr) | Anticorps anti-mct1 et utilisations associées | |
| EP3749320A4 (fr) | Aminoptérine alpha-polyglutamatée et utilisations associées | |
| EP3733702A4 (fr) | Anticorps anti-lag-3 et utilisations associées | |
| EP3810172A4 (fr) | Protéines hétérodimères et utilisations associées | |
| EP3570829A4 (fr) | Ligands photoréactifs et utilisations | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| EP3883967A4 (fr) | Anticorps anti-cd38 et anti-icam1 et utilisations correspondantes | |
| EP4093768A4 (fr) | Constructions cal-t et leurs utilisations | |
| EP3893945A4 (fr) | Esters cromoglycique et leurs utilisations | |
| EP3838900A4 (fr) | Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées | |
| MA52190A (fr) | Anticorps anti-trem-1 et utilisations associées |